These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15274760)

  • 1. [Pharmacoeconomics and cardiovascular disease].
    Anguita Sánchez M
    Rev Clin Esp; 2004 Aug; 204(8):391-2. PubMed ID: 15274760
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
    Detsky AS
    Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
    Gagnon JP
    Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599
    [No Abstract]   [Full Text] [Related]  

  • 4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.
    Hlatky MA
    Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595
    [No Abstract]   [Full Text] [Related]  

  • 5. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care.
    Stewart A; Schmier JK; Luce BR
    Am Heart J; 1999 May; 137(5):S53-61. PubMed ID: 10220598
    [No Abstract]   [Full Text] [Related]  

  • 6. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics.
    Califf RM
    Am Heart J; 1999 May; 137(5):S35-7. PubMed ID: 10220593
    [No Abstract]   [Full Text] [Related]  

  • 7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
    Temple R
    Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
    [No Abstract]   [Full Text] [Related]  

  • 8. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information.
    Morris LA
    Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603
    [No Abstract]   [Full Text] [Related]  

  • 9. The cost effectiveness of cardiovascular medicines.
    Hay J
    Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719
    [No Abstract]   [Full Text] [Related]  

  • 10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis.
    DeLong ER; Simons T
    Am Heart J; 1999 May; 137(5):S47-50. PubMed ID: 10220596
    [No Abstract]   [Full Text] [Related]  

  • 11. Current trends in cardiovascular therapy.
    Palmaz JC
    J Cardiovasc Surg (Torino); 2009 Feb; 50(1):3-6. PubMed ID: 19179985
    [No Abstract]   [Full Text] [Related]  

  • 12. Orphan Drug Development in Cardiovascular Medicine.
    Khan MS; Vaduganathan M; Butler J
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006509. PubMed ID: 32552063
    [No Abstract]   [Full Text] [Related]  

  • 13. What future does the pharmaceutical industry have in the cardiovascular world?
    Braunwald E
    Eur Heart J; 2013 Apr; 34(13):943-4. PubMed ID: 23546415
    [No Abstract]   [Full Text] [Related]  

  • 14. The cost-effectiveness of cardiovascular medicine in Greece: brief notes.
    Vardas PE
    Hellenic J Cardiol; 2012; 53(4):333-4. PubMed ID: 22796825
    [No Abstract]   [Full Text] [Related]  

  • 15. Merck Serono targets convenient, affordable medicines for patients at risk.
    Cardiovasc J Afr; 2009; 20(1):77. PubMed ID: 19287822
    [No Abstract]   [Full Text] [Related]  

  • 16. The Canadian Cardiovascular Society and reference-based drug pricing.
    Olley PM; McLaughlin PR
    Can J Cardiol; 1998 May; 14(5):669-70. PubMed ID: 9627521
    [No Abstract]   [Full Text] [Related]  

  • 17. The cost-effectiveness of cardiovascular medicine: victims of our own success?
    Vardas PE
    Hellenic J Cardiol; 2013; 54(2):155-6. PubMed ID: 23557621
    [No Abstract]   [Full Text] [Related]  

  • 18. ACE inhibitors: back to prime time?
    Gupta M; Verma S; Mancini GB
    Heart; 2007 Sep; 93(9):1015-6. PubMed ID: 17699166
    [No Abstract]   [Full Text] [Related]  

  • 19. The Imminent Demise of Cardiovascular Drug Development.
    Packer M
    JAMA Cardiol; 2017 Dec; 2(12):1293-1294. PubMed ID: 29117286
    [No Abstract]   [Full Text] [Related]  

  • 20. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Cardiovascular Society.
    Can J Cardiol; 1997 Jan; 13(1):33-45. PubMed ID: 9039063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.